2003 Fiscal Year Final Research Report Summary
Tailor-made chemotherapy against malignant gliomas based on chemosensitivity test and analysis of drug resistance gene
| Project/Area Number |
14571325
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Cerebral neurosurgery
|
|---|
| Research Institution | Yokohama City University |
|---|
Principal Investigator |
HAYASHI Akimune Yokohama City University School of Medicine, Neurosurgery, Associate Professor, 医学部附属病院, 助教授 (60285103)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
ONO Atsushi Yokohama City University School of Medicine, Neurosurgery, Instructor, 医学部附属病院, 助手 (10347346)
KANNO Hiroshi Yokohama City University School of Medicine, Neurosurgery, Associate Professor, 大学院・医学研究科, 助教授 (40244496)
|
|---|
| Project Period (FY) |
2002 – 2003
|
| Keywords | malignant glioma / chemosensitivity test / drug resistance gene / tailor made therapy / chemotherapy |
|---|
| Research Abstract |
Each malignant glioma shows different effect of anti-cancer drug. This mechanism could be related to expression of drug resistance gene. Effect of anti-cancer drug in vitro is examined with chemosensitivity test. Tailor made chemotherapy for malignant glioma was based on chemosensitivity test with collagen gel matrix method. In addition, mRNA expression of drug resistance gene was analyzed with RT-PCR method. Fifty-three cases of malignant gliomas (anaplastic astrocytoma, glioblastoma) were examined Tumor tissues obtained at surgery were cultured for 8 days for chemosensitivity test with collagen gel matrix method for 6 to 9 anti-cancer drugs. According to chemosensitivity, tow anti-cencer drugs were selected and injected through intra-arterial route. In addition, total RNA was extracted and RT-PCR method was performed for drug resistance genes such as MDR and Topo II. The result of chemosensitivity test was compared with expressions of drug resistance genes. Mean inhibition rate of tumor growth in chemosensitivity test showed 42.7% in CBDCA, 37.9% in CDDP, 30.8% in ACNU, and 3.2% in VCR. This result revealed high sensitivity in platinum drugs. Drug resistance gene expression was not significantly correlated with chemosensitivity (p=0.1). In addition, mean survival period of patients undergone with tailor made chemotherapy based on chemosensitivity test was not significantly different from mean survival period of patients undergone with conventional chemotherapy (p=0.07). In spite of small number of examined cases, tailor made chemotherapy should be further investigated.
|
